Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHC.L Regulatory News (PHC)

  • There is currently no data for PHC

Board Appointment

2 Feb 2009 11:01

RNS Number : 6266M
Plant Health Care PLC
02 February 2009
 



02 February 2009

Plant Health Care plc

("Plant Health Care" or "the Company")

NEW BOARD APPOINTMENT

Plant Health Care (AIM: PHC.L), a leading provider of natural products to the agriculture and landscape industries, announces that Dr. Dominik Koechlin was appointed to its Board as a non-executive director on 30 January 2009.

Dr. Koechlin, 50, a Swiss national, graduated from the University of Berne with a doctorate in law. He also has an MBA from INSEAD, Fontainebleau, France. Dr. Koechlin is currently a non-executive director of LGT Bank in Liechtenstein, and the following Swiss-listed companies: EGL AG, Swissmetal AG and Clariant AG.

Dr. Koechlin began his career working at Bank Sarasin in Basel from 1986 to 1988. He founded Ellipson AG in 1990, a business and management consultancy specialised in environmentally sound management and corporate financing. From 1996, he was a member of the executive committee of Telecom PTT and Swisscom AG.

During his time at Swisscom, the leading telecommunications provider in Switzerland, Dr. Koechlin was responsible for the redesign of the Swisscom business model, preparation for the IPO of Swisscom and development and communication of corporate strategy, as well as the international participations of Swisscom. Since 2001, Dr. Koechlin has worked as an independent board member and consultant for a number of listed and private businesses.

Dr. Albert Fischer, Non-executive Chairman of Plant Health Care commented:: "Dr. Koechlin has a great deal of experience in advising profitable, high-growth listed companies and will be a very strong addition to the Plant Health Care Board."

There is no other information that is required to be disclosed pursuant to Schedule 2 paragraph (g) of the AIM Rules, save as set out below:

Dominik Koechlin

Current Directorships

Past Directorships within last 5 years

LGT Bank in Liechtenstein Limited

Crucell NV

Elektrizitäts-Gesellschaft Laufenburg AG

Sustainable Asset Management AG

Swissmetal AG

Berna Biotech AG

Clariant AG

Novavox AG

Avaloq AG

Hesperion AG

M2 AG

Corris AG

- ends -

For further information:

John Brady

Evolution Securities Limited

Tavistock Communications

Chief Executive

Tim Worlledge/Tim Redfern

Jeremy Carey/Simon Compton

Tel: 001 603 525 3702

Tel: 020 7071 4300

Tel: 020 7920 3150

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAILFEIFAIFIIA
Date   Source Headline
28th Jun 202312:29 pmRNSHolding(s) in Company
27th Jun 20234:08 pmRNSHolding(s) in Company
27th Jun 20231:08 pmRNSDirector Shareholding
23rd Jun 20237:00 amRNSResult of Fundraising
22nd Jun 20234:35 pmRNSFundraising to raise up to US$3.6 million
14th Jun 20237:00 amRNSWilbur Ellis Agreement
13th Jun 20231:43 pmRNSResult of AGM
30th May 20237:00 amRNSHolding(s) in Company
24th May 20231:12 pmRNSHolding(s) in Company
19th May 20235:55 pmRNSPublication of Annual Report and Notice of AGM
18th May 20237:00 amRNSResult of Consultation
9th May 20237:00 amRNSPHC68949 granted first stage of approval in Brazil
2nd May 20237:10 amRNSResults for the year ended 31 December 2022
12th Apr 20232:33 pmRNSNotice of Results
5th Apr 20235:29 pmRNSHolding(s) in Company
8th Mar 20232:45 pmRNSExercise of Options
2nd Mar 20237:00 amRNSBiofungicide PHC279 Approved by US EPA
1st Mar 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Statement
30th Jan 202312:08 pmRNSSignificant Shareholder
18th Jan 20237:00 amRNSBoard Appointments
12th Jan 20237:00 amRNSNovozymes Distribution Agreement
9th Jan 20237:00 amRNSInvestor Presentation
22nd Dec 20227:00 amRNSNew Products Submitted for Regulatory Approval
28th Oct 20227:00 amRNSRegistration of Harpin in France
28th Oct 20227:00 amRNSNew distribution agreement with EDAF
27th Oct 20227:00 amRNSTrading Update
14th Oct 20225:11 pmRNSDirector/PDMR Shareholding
14th Oct 202210:39 amRNSDirector / PDMR Shareholding
26th Sep 20227:00 amRNSInterim Results
22nd Aug 20227:00 amRNSTrials agreement signed with Agrii UK
12th Aug 20227:00 amRNSGrant of Options
10th Aug 20225:04 pmRNSDirector/PDMR Shareholding
21st Jul 20222:41 pmRNSHolding(s) in Company
18th Jul 20227:02 amRNSInvestor Presentation
18th Jul 20227:00 amRNSPost-Close Trading Update
22nd Jun 202212:37 pmRNSResult of AGM
21st Jun 20227:00 amRNSCompletion of Nominated Adviser due diligence
20th Jun 20227:00 amRNSLong-term Harpin Production and Supply Agreement
6th Jun 20228:00 amRNSHolding(s) in Company
6th Jun 20228:00 amRNSHolding(s) in Company
1st Jun 20222:31 pmRNSDirector/PDMR Shareholding
25th May 20225:23 pmRNSHolding(s) in Company
23rd May 20227:30 amRNSAnnual Report & Accounts and Notice of AGM
23rd May 20227:00 amRNSNew distribution agreement with Nutrien
16th May 20227:00 amRNSHolding(s) in Company
12th May 20227:15 amRNSCEO appointment and Board changes
12th May 20227:00 amRNSResults for the year ended 31 December 2021
28th Apr 20227:00 amRNSChange of Adviser
21st Apr 20222:27 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.